Collectively, tylosin TMDI-treated mice showed an increased PBA/SBA ratio, as well as lower FGF15 levels in the ileum and portal vein, and decreased expression of hepatic FGFR4, which may cause metabolic disorders by affecting metabolism-related signaling pathways in the liver (46, –, 48). Here, FGFR4 is linked to metabolic disease.